Bioventix Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Bioventix.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 37.3% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 28 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Estimating The Fair Value Of Bioventix PLC (LON:BVXP)
Jun 19Bioventix's (LON:BVXP) Dividend Will Be £0.68
Mar 29We Think Shareholders May Consider Being More Generous With Bioventix PLC's (LON:BVXP) CEO Compensation Package
Dec 01Bioventix (LON:BVXP) Is Increasing Its Dividend To £0.62
Mar 30Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52
Mar 31Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?
Mar 29Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?
Mar 14What Does Bioventix's (LON:BVXP) CEO Pay Reveal?
Feb 27Shareholders of Bioventix (LON:BVXP) Must Be Delighted With Their 364% Total Return
Jan 31Is Bioventix PLC (LON:BVXP) Popular Amongst Insiders?
Jan 18Is Bioventix PLC's (LON:BVXP) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 06Here's How We Evaluate Bioventix PLC's (LON:BVXP) Dividend
Dec 23Does Bioventix's (LON:BVXP) CEO Salary Compare Well With Industry Peers?
Nov 28Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
6/30/2025 | 15 | 9 | 8 | 11 | 1 |
6/30/2024 | 14 | 8 | 8 | 8 | N/A |
3/31/2024 | 14 | 8 | 8 | 8 | N/A |
12/31/2023 | 14 | 9 | 8 | 8 | N/A |
9/30/2023 | 13 | 9 | 8 | 8 | N/A |
6/30/2023 | 13 | 8 | 8 | 8 | N/A |
3/31/2023 | 13 | 8 | 8 | 8 | N/A |
12/31/2022 | 13 | 8 | 8 | 8 | N/A |
9/30/2022 | 12 | 8 | 8 | 8 | N/A |
6/30/2022 | 12 | 8 | 8 | 8 | N/A |
3/31/2022 | 11 | 7 | 7 | 7 | N/A |
12/31/2021 | 10 | 7 | 7 | 7 | N/A |
9/30/2021 | 11 | 7 | 6 | 7 | N/A |
6/30/2021 | 11 | 7 | 6 | 6 | N/A |
3/31/2021 | 11 | 7 | 6 | 7 | N/A |
12/31/2020 | 10 | 7 | 7 | 7 | N/A |
9/30/2020 | 10 | 7 | 7 | 7 | N/A |
6/30/2020 | 10 | 7 | 7 | 8 | N/A |
3/31/2020 | 10 | 7 | 7 | 7 | N/A |
12/31/2019 | 10 | 7 | 6 | 7 | N/A |
9/30/2019 | 10 | 6 | 6 | 6 | N/A |
6/30/2019 | 9 | 6 | 6 | 6 | N/A |
3/31/2019 | 9 | 6 | 6 | 6 | N/A |
12/31/2018 | 9 | 6 | 6 | 6 | N/A |
9/30/2018 | 9 | 6 | 6 | 6 | N/A |
6/30/2018 | 9 | 6 | 6 | 6 | N/A |
3/31/2018 | 9 | 6 | N/A | 5 | N/A |
12/31/2017 | 8 | 6 | N/A | 5 | N/A |
9/30/2017 | 8 | 5 | N/A | 4 | N/A |
6/30/2017 | 7 | 5 | N/A | 4 | N/A |
3/31/2017 | 7 | 5 | N/A | 4 | N/A |
12/31/2016 | 6 | 4 | N/A | 4 | N/A |
9/30/2016 | 6 | 4 | N/A | 3 | N/A |
6/30/2016 | 6 | 3 | N/A | 3 | N/A |
3/31/2016 | 5 | 3 | N/A | 3 | N/A |
12/31/2015 | 5 | 3 | N/A | 2 | N/A |
9/30/2015 | 5 | 3 | N/A | 2 | N/A |
6/30/2015 | 4 | 3 | N/A | 2 | N/A |
3/31/2015 | 4 | 2 | N/A | 2 | N/A |
12/31/2014 | 4 | 2 | N/A | 2 | N/A |
9/30/2014 | 4 | 2 | N/A | 2 | N/A |
6/30/2014 | 4 | 2 | N/A | 2 | N/A |
3/31/2014 | 3 | 2 | N/A | 2 | N/A |
12/31/2013 | 3 | 2 | N/A | 2 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if BVXP's forecast earnings growth is above the savings rate (1.9%).
Beneficios vs. Mercado: Insufficient data to determine if BVXP's earnings are forecast to grow faster than the UK market
Beneficios de alto crecimiento: Insufficient data to determine if BVXP's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if BVXP's revenue is forecast to grow faster than the UK market.
Ingresos de alto crecimiento: Insufficient data to determine if BVXP's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if BVXP's Return on Equity is forecast to be high in 3 years time